Evidence map›Paper›PMID 40980200›Full record

ArticleNew microbes and new infections2025

Enhanced immunogenicity of COVID-19 RBD fused to mutant scorpion's phospholipase D for vaccine development.

Mohammad-Reza Zareinejad, Mahdi Behdani, Mohammad Taghi Goodarzi, Akbar Oghalaie, Mohammad Hosseininejad-Chafi, Kamran Pooshang-Bagheri, Delavar Shahbazzadeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New microbes and new infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammad-Reza ZareinejadDepartment of Biochemistry, Shahrood Branch, Islamic Azad University, Shahrood, Iran.
Mahdi BehdaniVenom and Biotherapeutics Molecules Laboratory, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Mohammad Taghi GoodarziDepartment of Biochemistry, Shahrood Branch, Islamic Azad University, Shahrood, Iran.
Akbar OghalaieVenom and Biotherapeutics Molecules Laboratory, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Mohammad Hosseininejad-ChafiVenom and Biotherapeutics Molecules Laboratory, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Kamran Pooshang-BagheriVenom and Biotherapeutics Molecules Laboratory, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Delavar ShahbazzadehVenom and Biotherapeutics Molecules Laboratory, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of the global COVID-19 pandemic relies, in part, on the rapid development of preventive vaccines at an unparalleled speed. The infection caused by the coronavirus is facilitated by the spike glycoprotein trimmer located on the surface of the virion, specifically through its receptor binding domain (RBD). The response of antibodies to this domain is a key indicator of the immunization's effectiveness and is well correlated with the neutralization of the viral agent. The failure of COVID-19 vaccines to induce complete neutralization provides an opportunity to find an alternative way. In this study, we show that recombinant RBD, Wuhan-specific; fused to mPLD1 protein, a highly effective immunogen from

Indexed as

Conventional virus neutralizing testCovid-19 vaccineHemiscorpius lepturus scorpionMutant phospholipase DReceptor binding domainVaccine

Identifiers

PMID40980200
PMCPMC12446496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.